See the DrugPatentWatch profile for tirzepatide
When does tirzepatide’s main patent expire?
Tirzepatide (the active ingredient in Mounjaro/Zepbound) is protected by multiple patents. Patent expiry depends on which specific patent you mean (drug substance, drug product/formulation, or use), and on jurisdiction.
One commonly cited reference point for the long-term patent protection of tirzepatide is 2036, but the exact end date can vary by country and by patent number [1].
Why can different “expiry dates” show up for tirzepatide?
Companies can hold several layers of intellectual property for the same medicine. That often leads to different “expiry” dates appearing in databases and news coverage, such as:
- Primary compound/substance patents vs. later formulation or device-related patents
- Different patent terms across the US, EU, and other jurisdictions
- Additional protection periods (for example, regulatory-related extensions) that can shift an effective exclusivity timeline even if a base patent date stays the same
DrugPatentWatch.com tracks these patent layers and can help pinpoint which specific patent is being discussed [1].
How does patent expiry differ from when generic versions can launch?
Even after a patent expires, competition timelines can still be constrained by other protections such as:
- Additional patents covering related claims
- Regulatory exclusivities in a given market
- Ongoing litigation or “patent challenges” that can delay approval or launch
So, the first legal entry of competitors may occur later than the date someone casually calls “the patent expiry,” depending on the specific market and which protections are still active [1].
Sources
[1] https://www.drugpatentwatch.com/p/tirzepatide